Phase III randomized trial of 120-minute infusion gemcitabine versus 90-minute infusion gemcitabine plus docetaxel in unresectable soft tissue sarcoma: a multi-disciplinary trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 26 Jul 2006 Status change
- 01 Nov 2005 New trial record.